Associated tags: Genetic engineering, Gout, Synthetic biology, Probiotic, IBD, Inflammatory bowel disease, Roche, PKU, Homocystinuria, Phenylketonuria, HCU, Uric acid, AbbVie, Pharmaceutical industry, Therapy, Patient, FDA, Research
Locations: NEW YORK CITY, LOS ANGELES, INN, CULVER CITY, CA, CAMBRIDGE, MA, US, CALIFORNIA, UNITED STATES, ROCHE, BOSTON, CANADA
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023.
Key Points:
- CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023.
- As of December 31, 2023, Synlogic had cash, cash equivalents, and short-term marketable securities of $47.7 million.
- Revenue was $2.8 million for the three months ended December 31, 2023, compared to $0.1 million for the corresponding period in 2022.
- Revenues were $3.4 million for the year ended December 31, 2023, compared to $1.2 million for the same period in 2022.
Retrieved on:
Tuesday, February 20, 2024
The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025.
Key Points:
- The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025.
- The Board adopted the Rights Plan following an unsolicited accumulation of Synlogic shares by a certain investor.
- A Rights Plan will enable the Board and Synlogic’s management team to protect stockholders while fulfilling its fiduciary responsibilities to review and evaluate strategic alternatives intended to maximize long-term value for all Synlogic stockholders.
- The Rights Plan is similar to other plans adopted by publicly held companies in comparable circumstances and is intended to enable all stockholders to realize the long-term value of their investment in Synlogic.
Retrieved on:
Thursday, February 8, 2024
Workforce,
News,
Acquisition,
Partnership,
Investment,
Therapy,
Safety,
Data monitoring committee,
DMC,
PKU,
Science,
Phenylketonuria,
Disclosure,
Management CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for phenylketonuria (PKU). As a result, Synlogic’s management and its Board of Directors have made the decision to evaluate strategic options for the Company.
Key Points:
- As a result, Synlogic’s management and its Board of Directors have made the decision to evaluate strategic options for the Company.
- The decision was not based on concerns regarding safety or tolerability.
- Synlogic will now work with the Synpheny-3 clinical trial sites involved to implement the discontinuation.
- "It is with a heavy heart that we share this news, and our resulting decision to end Synpheny-3.
Nature,
Manuscript,
Met,
Homocysteine,
AbbVie,
Trial of the century,
Cell Host & Microbe,
Absorption,
Research,
Therapy,
Patient,
Safety,
Methionine,
Extrapyramidal system,
Plasma,
HCU,
Dietary supplement CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU).
Key Points:
- Among findings outlined in the manuscript, SYNB1353 efficiently degraded both dietary and entero-recirculating methionine to prevent its absorption and subsequent conversion to homocysteine in preclinical models, suggesting that SYNB1353 should result in lowering of plasma homocysteine levels in HCU patients.
- In addition, in results from the clinical study in healthy volunteers, SYNB1353 was generally well-tolerated and adverse events were mild to moderate, transient, and predominantly gastrointestinal in nature.
- The proportion of subjects reporting gastrointestinal events were similar for the SYNB1353 and placebo cohorts (36.4% and 37.5%, respectively).
- “Importantly, the SYNB1353 program has built on learnings and progress from our other rare metabolic disease programs, including the design of the potential therapeutic, the preclinical research and the advancement in clinical development.”
The publication, entitled “The Live Biotherapeutic SYNB1353 Decreases Plasma Methionine via Directed Degradation in Animal Models and Healthy Volunteers,” and published in the peer-reviewed journal, Cell Host & Microbe, is now available online at https://www.sciencedirect.com/science/article/pii/S193131282400009X .
Retrieved on:
Thursday, January 4, 2024
Conference,
Food,
AbbVie,
Met,
Nature Metabolism,
Homocysteine,
FDA,
Plasma,
DMC,
Annual general meeting,
Diet,
Ageing,
Trial of the century,
Society,
GI,
Data monitoring committee,
Phenylalanine,
Part,
SIMD,
PKU,
HCU,
Patient,
Safety,
Pharmaceutical industry CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today summarized accomplishments for 2023 and anticipated key milestones for 2024.
Key Points:
- “We are pleased with the important corporate progress we achieved in 2023 - highlighted by the initiation of our global pivotal Synpheny-3 study evaluating our potentially transformative treatment option for PKU,” said Aoife Brennan, M.B.
- Ch.B., Synlogic President and Chief Executive Officer.
- “We expect 2024 to be similarly momentous, with the achievement of key milestones, including the upcoming Data Monitoring Committee review of initial study data.
- More information on the Synpheny-3 study is available at www.clinicaltrials.gov, identifier NCT05764239 and also by visiting pkuresearchstudy.com.
Retrieved on:
Wednesday, December 27, 2023
CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to develop a manufacturing process to support development of a potential live probiotic product.
Key Points:
- CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to develop a manufacturing process to support development of a potential live probiotic product.
- Synlogic’s activities on this project are expected to start in Q1 2024 and will be complete in Q1 2025.
Retrieved on:
Thursday, December 7, 2023
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), including findings from fermentation process improvements to increase activity of methionine degradation, has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.
Key Points:
- CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), including findings from fermentation process improvements to increase activity of methionine degradation, has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.
- Poster presentation details are as follows:
For more information, please visit the conference website .
- The poster will be available following the conference on the Synlogic website.
Retrieved on:
Thursday, November 9, 2023
FDA,
Research,
PKU,
Patent,
AbbVie,
PAL,
International Conference on Nuclear Disarmament, Oslo, 2008,
Homocystinuria,
Treatment,
University,
Conference,
Progress,
Phenylketonuria,
Partnership,
Head,
United States patent law,
Methionine,
Lead,
Pittsburgh,
Investment,
Inflammatory bowel disease,
Nature Metabolism,
Nursing,
Pharmaceutical industry,
Cryptocurrency,
Vitro CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
Key Points:
- Publication of Synpheny-1 Phase 2 study results for the PKU program in the journal Nature Metabolism.
- Presentation of Synpheny-1 Phase 2 study results by lead investigator Dr. Jerry Vockley of the University of Pittsburgh at the 37th E.S.PKU Conference 2023.
- Revenue for the three months ended September 30, 2023 was $0.4 million compared to $0.7 million for the corresponding period in 2022.
- General and administrative expenses were $3.4 million for the three months ended September 30, 2023, compared to $4.4 million for the corresponding period in 2022.
Retrieved on:
Tuesday, November 7, 2023
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced today that it has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million due under its collaboration agreement with Roche for the research and pre-clinical development of a Synthetic Biotic for the treatment of inflammatory bowel disease (IBD).
Key Points:
- CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced today that it has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million due under its collaboration agreement with Roche for the research and pre-clinical development of a Synthetic Biotic for the treatment of inflammatory bowel disease (IBD).
- “The field of IBD presents a clear need for therapeutic innovation, and there is a compelling fit with the disease biology and the locally acting, gut-restricted approach of Synthetic Biotics,” said Mylene Perreault, Ph.D., Vice President and Head of Research at Synlogic.
- “We are proud of the joint research team’s progress and accomplishments achieved through this collaboration, and our contribution towards a new potential biotherapeutic for IBD.”
Pursuant to the terms of the research collaboration agreement, Synlogic and Roche collaborated to develop a Synthetic Biotic to address an undisclosed novel target in IBD.
- Roche has the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the product candidate.
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the closing of its previously announced underwritten public offering.
Key Points:
- CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the closing of its previously announced underwritten public offering.
- The combined effective offering price to the public of each share of common stock (or pre-funded warrant) and accompanying warrant was $2.84.
- The aggregate gross proceeds to Synlogic from the public offering were approximately $21.0 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses.
- Synlogic anticipates existing cash and cash equivalents and the proceeds from this offering will be sufficient to fund planned operations into the first half of 2025.
